Results 191 to 200 of about 877,301 (350)

Computers Can Change Cardiology [PDF]

open access: bronze, 1973
Andrew G. Wallace, Robert A. Rosati
openalex   +1 more source

Trends in first‐line monotherapy and combination therapy for hypertension in UK primary care

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Debate remains about the optimal initial treatment strategy for hypertension. Most guidelines recommend first‐line combination therapy for most patients. However, the UK's National Institute for Health and Care Excellence recommends first‐line monotherapy for all patients.
Kyle Johnson   +4 more
wiley   +1 more source

Cardiovascular disease in North African women: insights from the Middle East African Women CardioVascular Disease (MEA-WCVD) registry. [PDF]

open access: yesFront Cardiovasc Med
Charfeddine S   +83 more
europepmc   +1 more source

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr   +18 more
wiley   +1 more source

Correction: Impact of cardiac rehabilitation and treatment compliance after ST-segment elevation myocardial infarction (STEMI) in France, the STOP SCA+ study. [PDF]

open access: yesFront Cardiovasc Med
Laurent E   +10 more
europepmc   +1 more source

Fostamatinib and the risk of acute aortic dissection in immune thrombocytopenia

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by platelet destruction. While most patients respond to first‐ or second‐line therapies, a small subset is multirefractory. Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, is a therapeutic option in these cases.
Paul Dalmas   +7 more
wiley   +1 more source

A Synopsis of Cardiology

open access: bronze, 1964
David Weitzman
openalex   +1 more source

Home - About - Disclaimer - Privacy